Q-omics provides the consensus-scored CLEC6A profile across patient tissues and cancer cell-line models. CLEC6A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CLEC6A is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, CLEC6A RNA expression shows 13,433 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KICH, and TGCT as cancer lineages where CLEC6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC6A survival associations across molecular data types. CLEC6A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC6A RNA expression–survival associations across cancer types. High CLEC6A expression shows unfavorable associations in THYM, but favorable associations in SKCM, HNSC, ESCA, COAD and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CLEC6A RNA expression.
This table summarizes CLEC6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC6A shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in COAD, HNSC and STAD. The KICH box plot shows higher CLEC6A RNA expression in normal versus tumor tissue (log2 FC = −0.276, t-test p < 0.001).
This table shows molecular features associated with CLEC6A in patient tissues and cancer cell lines. In patient samples, CLEC6A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
